Clinical Research Directory
Browse clinical research sites, groups, and studies.
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Summary
The second generation of mesothelin targeted CAR-T cells that secret a fusion protein of IL21 and scfv against PD1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-T cells for immunotherapy of human cancer patients with Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the Mesothelin-CAR-T cell immunotherapy on human cancers will firstly be evaluated.
Official title: Mesothelin/GPC3/GUCY2C Targeted CAR-T for Immunotherapy of Pancreatic Cancer: Phase I Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-03-10
Completion Date
2036-03-10
Last Updated
2024-06-25
Healthy Volunteers
No
Interventions
CAR-T cells
Transfer CAR-T cells into patients for anti-ancer therapy.
Locations (1)
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China